- Home
- VKTX vs AKRO Comparison
VKTX vs AKRO Comparison
Compare VKTX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- AKRO
- Stock Information
- Founded
- VKTX 2012
- AKRO 2017
- Country
- VKTX United States
- AKRO United States
- Employees
- VKTX N/A
- AKRO N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- VKTX Health Care
- AKRO Health Care
- Exchange
- VKTX Nasdaq
- AKRO Nasdaq
- Market Cap
- VKTX 3.4B
- AKRO 2.8B
- IPO Year
- VKTX 2015
- AKRO 2019
- Fundamental
- Price
- VKTX $23.94
- AKRO $37.63
- Analyst Decision
- VKTX Strong Buy
- AKRO Strong Buy
- Analyst Count
- VKTX 12
- AKRO 9
- Target Price
- VKTX $89.75
- AKRO $76.29
- AVG Volume (30 Days)
- VKTX 4.5M
- AKRO 1.3M
- Earning Date
- VKTX 04-23-2025
- AKRO 05-09-2025
- Dividend Yield
- VKTX N/A
- AKRO N/A
- EPS Growth
- VKTX N/A
- AKRO N/A
- EPS
- VKTX N/A
- AKRO N/A
- Revenue
- VKTX N/A
- AKRO N/A
- Revenue This Year
- VKTX N/A
- AKRO N/A
- Revenue Next Year
- VKTX N/A
- AKRO N/A
- P/E Ratio
- VKTX N/A
- AKRO N/A
- Revenue Growth
- VKTX N/A
- AKRO N/A
- 52 Week Low
- VKTX $18.92
- AKRO $17.86
- 52 Week High
- VKTX $81.86
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- VKTX 46.06
- AKRO 43.61
- Support Level
- VKTX $18.92
- AKRO $36.46
- Resistance Level
- VKTX $27.09
- AKRO $39.13
- Average True Range (ATR)
- VKTX 2.31
- AKRO 3.04
- MACD
- VKTX 0.26
- AKRO 0.06
- Stochastic Oscillator
- VKTX 61.44
- AKRO 57.38
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.